I just came across an article in the AFR which points to the inhaled version of heparin improving the outcome for COVID-19 patients. Since PPS shares similarities to Heparin, maybe PAR should pursue this avenue for ARDs instead of subcutaneous injections of iPPS. This could also help revive the inhaled formation of PPS after the failed hayfever P2A trial.
Some articles that may be of interest to some:
Title: Unfractionated heparin inhibits live wild type SARS-CoV-2 cell infectivity at therapeutically relevant concentrations
https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bph.15304
Title: Inhaled nebulised unfractionated heparin for the treatment of hospitalised patients with COVID-19: A multicentre case series of 98 patients.
https://europepmc.org/article/MED/34984714
Should PAR revive the inhaled PPS formulation?
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.5¢ |
Change
-0.015(5.77%) |
Mkt cap ! $85.70M | |||
| Open | High | Low | Value | Volume |
| 26.0¢ | 26.0¢ | 24.5¢ | $265.4K | 1.050M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 130186 | 24.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.0¢ | 11571 | 1 |
View Market Depth
| Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |